Nav: Home

Heart valve procedure safe for patients with common heart defect

June 11, 2019

LOS ANGELES (EMBARGOED UNTIL JUNE 11, 2019 at 11 A.M. EDT) -- A new analysis conducted by investigators at the Cedars-Sinai Smidt Heart Institute shows for the first time that patients with a common heart defect who undergo catheter-based valve replacement procedures have the same survival and complication rates as patients without the defect who undergo the same procedure.

Published June 11 in JAMA: The Journal of the American Medical Association, the analysis compares outcomes for 2,726 patients born with a bicuspid aortic valve-two leaflets that open and close with every heartbeat-with 79,096 patients born with the normal three leaflets on their aortic valves. Both groups of patients were diagnosed with aortic stenosis, a stiffness of the valve's leaflets that reduces the ability to fully open and close and causes the heart's aortic valve to narrow and the heart muscle to become thicker and sometimes weaker.

Aortic stenosis usually affects people 60 and older, but patients born with bicuspid aortic valve often experience it at a younger age. About 1% of the population is born with bicuspid aortic valve.

TAVR (transcatheter aortic valve replacement) is a minimally invasive, catheter-based procedure during which an interventional cardiologist repairs the valve by placing a new valve into the aorta. For patients with normal aortic valves, the procedure is generally considered less risky and easier to recover from than open-heart surgery. But until now, there was not enough data to prove the TAVR procedure also is safe for patients with bicuspid valves.

"In our analysis, we looked at all the bicuspid anatomy patients and found that death rates were no different than patients who had the normal number of leaflets and TAVR," said Raj Makkar, MD, vice president of Cardiovascular Innovation and Intervention at Cedars-Sinai and the Stephen R. Corday Chair in Interventional Cardiology. "This is important because many of the pivotal studies on TAVR did not include bicuspid patients due to concern that these valves may not expand and work in fish-mouth like narrowing in bicuspid anatomy."

The analysis also showed that bicuspid patients were slightly more likely than tricuspid patients to have a stroke within 30 days of the procedure. Based on these findings, Makkar says "carefully selected patients with bicuspid aortic valve stenosis can be treated with TAVR, sparing them more invasive open-heart surgery and longer recovery times since most patients can be discharged home the day after the procedure."

Makkar's TAVR analysis of patients at 552 U.S. medical centers showed:
  • 2.6% of bicuspid patients died within 30 days of the procedure, compared to 2.5% of tricuspid patients, a difference that is not statistically significant.

  • 10.5% of bicuspid patients died within one year of the procedure, compared to 12% of tricuspid patients, a difference that is not statistically significant.

  • The 30-day stroke rate was higher for bicuspid patients (2.5%) than for tricuspid patients (1.6%).

  • The risk of procedural complications requiring open-heart surgery was significantly higher in the bicuspid group (0.9%) than the tricuspid cohort (0.4%).

  • Both groups experienced the same quality of life as measured by the Kansas City Cardiomyopathy Questionnaire.
"This study highlights a critical evaluation that may help some patients avoid unnecessary surgery and complications," said Eduardo Marbán, MD, PhD, director of the Smidt Heart Institute. "Here at Cedars-Sinai, we put the patient first. Many, but not all, patients with bicuspid aortic valve are candidates for TAVR. The care of each patient is individualized, and those who would benefit more from surgery will be appropriately managed by the appropriate faculty on our team."
Read more on the Cedars-Sinai blog: A Fresh Start After Open-Heart Surgery

Cedars-Sinai Medical Center

Related Aortic Valve Articles:

Study implicates 2 genetic variants in bicuspid aortic valve development
Researchers report a key protein is affected during heart valve formation, in the first genome-wide study of bicuspid aortic valve.
CT scans reveal reduced leaflet motion after aortic valve replacement
About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood clots around the valve leaflets (known as subclinical leaflet thrombosis) that reduced the motion of the valves, according to an observational study presented at the American College of Cardiology's 66th Annual Scientific Session.
Transcatheter aortic valve replacement as effective as surgery in intermediate patients
Medtronic plc (NYSE: MDT) today unveiled first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented at the American College of Cardiology (ACC) 66th Annual Scientific Session and published simultaneously in The New England Journal of Medicine (NEJM).
Smokers far more likely to develop abdominal aortic aneurysms
Smokers are nearly twice as likely to develop an abdominal aortic aneurysm as the general population.
New method for performing aortic valve replacement proves successful in high risk patients
Researchers at the National Institutes of Health (NIH) have developed a new, less invasive way to perform transcatheter aortic valve replacement (TAVR), a procedure widely used to treat aortic valve stenosis, a lethal heart condition.
Risk factors and clinical outcomes of infective endocarditis after transcatheter aortic valve replac
Among patients undergoing transcatheter aortic valve replacement, younger age, male sex, history of diabetes mellitus, and moderate to severe residual aortic regurgitation were significantly associated with an increased risk of infective endocarditis, and patients who developed endocarditis had high rates of in-hospital mortality and 2-year mortality, according to a study appearing in the Sept.
One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high risk and inoperable patients with severe aortic stenosis
Overall one-year survival was over 85 percent for high-risk or inoperable patients who underwent aortic valve replacement with the SAPIEN 3 trans-catheter aortic valve replacement system, according to a study published in the July 12 issue of the American Heart Association journal Circulation.
Penn researchers find one-third of patients with low flow aortic stenosis do not improve with transcatheter aortic valve replacement
For patients with low flow aortic stenosis, TAVR -- a minimally invasive procedure which corrects the damaged aortic valve -- is often the best option for restoring the heart's normal pumping function.
State of the art management of aortic disease
There have been exciting developments in caring for patients with aortic aneurysm and dissection, including great advances in diagnosis and endovascular therapies.
Study identifies aortic valve gradient as key to TAVR outcomes
Patients with a combination of left ventricular dysfunction and low aortic valve gradient, or reduced force of blood flow through the aortic valve, have higher mortality rates and a greater risk of recurrent heart failure after transcatheter aortic valve replacement (TAVR), with low aortic valve gradient the driving force behind their poor outcomes, according to a study published today in the Journal of the American College of Cardiology.

Related Aortic Valve Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...